Calidi Biotherapeutics (CLDI) Share-based Compensation (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Share-based Compensation of $450000.0 for Q4 2025, down 28.12% year-over-year from $626000.0 in Q4 2024, and down 14.93% quarter-over-quarter from $529000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Share-based Compensation (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $450000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation fell 28.12% year-over-year to $450000.0; the TTM figure through Dec 2025 stood at $2.1 million (down 28.69% YoY), while the FY2025 annual figure was $2.1 million, down 28.71% from the prior year.
- Share-based Compensation for Q4 2025 stood at $450000.0, down from $529000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $4.5 million in Q4 2023, with the low at $450000.0 in Q4 2025.
- The 4-year median for Share-based Compensation is $888000.0 (2024), against an average of $1.3 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation increased 4.43% in 2023, then plunged 85.98% in 2024.
- Calidi Biotherapeutics' Share-based Compensation stood at $4.3 million in 2022, then climbed by 3.02% to $4.5 million in 2023, then slumped by 85.98% to $626000.0 in 2024, then retreated by 28.12% to $450000.0 in 2025.
- Business Quant data shows CLDI's Share-based Compensation at $450000.0 in Q4 2025, $529000.0 in Q3 2025, and $522000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.98 Mn | -2.12 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Jun 30, 2026 | 400,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Sep 30, 2025 | 529,000.00 |
| Sep 30, 2025 | 529,000.00 |
| Jun 30, 2025 | 522,000.00 |
| Jun 30, 2025 | 522,000.00 |
| Mar 31, 2025 | 607,000.00 |
| Mar 31, 2025 | 607,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Dec 31, 2024 | 626,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Sep 30, 2024 | 691,000.00 |
| Jun 30, 2024 | 751,000.00 |
| Jun 30, 2024 | 751,000.00 |
| Mar 31, 2024 | 888,000.00 |
| Mar 31, 2024 | 888,000.00 |
| Dec 31, 2023 | 4.47 Mn |
| Dec 31, 2023 | 4.47 Mn |